Millions suffering needlessly with curable hepatitis C, new analysis reveals
Peer-Reviewed Publication
Updates every hour. Last Updated: 2-Jun-2026 05:16 ET (2-Jun-2026 09:16 GMT/UTC)
Millions of Americans are still battling potentially deadly hepatitis C even though they could be cured with antiviral drugs they are not receiving, a new analysis reveals. The alarming trend threatens both many Americans’ health and federal goals to eliminate the disease in the United States.
For most of the 20th century, cardiovascular disease (CVD) was perceived to be a predominantly male condition, leading to systematic under-recognition and under-treatment in women. Since its inception in 1948, the Framingham Heart Study (FHS), one of the longest-running epidemiological studies in the world, has changed this understanding by demonstrating that CVD is not only a major cause of morbidity and mortality in women, but that certain risk factors and subtypes of CVD may affect women more severely than men.
Using published reports with Framingham Heart Study data collected during nearly eight decades of follow-up, researchers concluded that women’s CVD is biologically different than CVD in men, and not just a delayed manifestation. These findings underline the need for risk assessment, prevention, and clinical care of CVD separately for men and women.
A review paper by scientists from Shenyang Institute of Automation, Chinese Academy of Science provided a comprehensive overview of cyborg animals within the framework of animal taxonomy, summarizing the current state of research from a zoological perspective.
The new research paper, published on Mar. 26 in the journal Cyborg and Bionic Systems, delivers a systematic, holistic overview of cyborg animals—revolutionary biohybrid robots that merge living organisms innate biological capabilities with artificial electromechanical control, addressing the fundamental limitations of traditional rigid silicon-based robots.
CAMBRIDGE, Mass., April 21, 2026 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the strategic formation of the industry’s first Longevity Board (Board). The initiative provides scientific oversight and strategic guidance for AI-enabled aging research and drug discovery, accelerating the development of therapeutics that target the fundamental biological processes of aging and advancing a shift from reactive disease care to proactive healthspan and peakspan extension. The Board will oversee the work in life models, biomarkers of aging, identification of dual-purpose targets implicated in aging, longevity and disease, and clinical development validating the effects of therapeutics on the hallmarks of aging using biomarkers and foundation models.
Researchers at Umeå University have identified two human cell proteins, NUP98 and NUP153, that play a crucial role in how viruses such as tick-borne encephalitis virus (TBEV), West Nile virus, and dengue virus replicate in the body. The findings challenge existing views of how these viruses exploit human cells and point to new, promising targets for future antiviral drugs.
Artificial intelligence (AI) is rapidly transforming heart failure (HF) management, offering advances from early risk prediction to treatment and continuous monitoring. A recent review led by Professor Yi-Da Tang highlights how AI integrates electronic health records, multimodal imaging, and wearable technologies to enable personalized HF care. While challenges in generalizability, interpretability, and reliability remain, ongoing innovation and validation efforts are expected to accelerate clinical translation and improve outcomes for HF patients.